Press Releases
Gateway Genomics Launches the SneakPeek Brand Affiliates Program to Build Community for Fetal Sex Detection
SneakPeek Early Gender DNA Test lets parents learn the sex of their baby at 8 weeks into pregnancy with 99.9% accuracy.
Gateway Genomics, market leader of direct-to-consumer genetic tests focused on prenatal and pediatric information, announces the launch of the new SneakPeek Brand Affiliates program that allows partners and supporters to promote SneakPeek Gender or Traits At-home products and receive a commission.
Gateway Genomics Launches the Breakthrough SneakPeek Snap Which Eliminates Need for Fingerstick Blood Collection from Fetal Sex Testing
SneakPeek Snap is the first and only push-button, microneedle-based device available for parents to learn the gender of their babies, months earlier than ultrasound.
Gateway Genomics, leading provider of direct-to-consumer genetic tests focused on prenatal and pediatric information, announces the launch of the new SneakPeek Snap. SneakPeek Snap is a self-administered device that collects capillary blood through the upper arm rather than the sensitive fingertip, thereby reducing pain from 78% to 10% as noted in a recent clinical study. The automated, self-contained nature of SneakPeek Snap also made it easier to use, reducing difficulty from 60% to 10%.
Gateway Genomics Publication Shows Breakthrough SneakPeek Snap Microneedle-based Device to be Virtually Painless
In the clinical study, 90% of participants found SneakPeek Snap to cause no pain, versus only 22% using the traditional lancet device for blood collection.
Gateway Genomics, leading provider of direct-to-consumer genetic tests focused on prenatal and pediatric information, announces a new publication titled, “SneakPeek Snap: A Painless Microneedle-Based Push-Button Device for Early Fetal Sex Determination” in the International Journal of Pregnancy & Child Birth.
Gateway Genomics Ranks No. 56 in the Inc. 5000 Series: California’s Fastest-Growing Private Companies for 2021
For the second straight year, Gateway Genomics ranks as one of the top private companies in the Health sector, which includes biotech, pharmaceutical firms, and makers of medical devise and products for the health care market.
Gateway Genomics, a leading developer of direct-to-consumer genetic tests that give families insight into their future children, was recognized in this year’s Inc. 5000’s California list for the second year in a row, emerging as the 56th fastest-growing private company in the state, and #6 in the Health sector. Last year the company was included in the 2020 annual Inc. 5000 list of fastest-growing private companies in the United States.
Gateway Genomics Surpasses 1000 Clinical Locations Across the US, UK, and Canada
Attracted by the ability to acquire new clients/patients early in pregnancy, provider signup for the SneakPeek Gender DNA Test climbed in 2020 and Q1 2021
Gateway Genomics, leading developer of direct-to-consumer genetic tests that give families insight into their future children, achieved a milestone of over 1,000 distributors of its SneakPeek Clinical test across the US, UK, and Canada. This number represents a doubling of locations since this time last year.
Landmark Large-scale Publication Shows SneakPeek Early Gender DNA Test Predicts Fetal Sex with 99.9% Accuracy, Months Before Ultrasound
In one of the largest clinical studies of its kind, Gateway Genomics' SneakPeek test predicted gender accurately for 1028 of 1029 women between 7-37 weeks into pregnancy.
Gateway Genomics, leading provider of direct-to-consumer genetic tests focused on prenatal and pediatric information, announces a new publication titled, “Large scale follow-up research study: SneakPeek® Early Gender DNA Test 99.9% accurate for fetal sex by live-birth confirmation” in the International Journal of Pregnancy & Child Birth.
Gateway Genomics Launches SneakPeek Early Traits DNA Test that Uses Genetics to Provide a Child’s Features
With this new product, the company that’s known for the SneakPeek Early Gender DNA Test provides a window into what a child will look like as an adult, predicted nutrition levels, and sleep behavior, as predicted by genetics.
Gateway Genomics, leading provider of direct-to-consumer genetic tests focused on prenatal and pediatric information, launches the SneakPeek Early Traits DNA Test for parents of young children to learn more about their unique child. The test offers fun insights on adult physical features as well as helpful tips and advice for predicted nutrition levels and sleep behavior as gleaned from the child’s DNA.
Gateway Genomics Surpasses 300,000 SneakPeek Early Gender DNA Tests Sold with Accelerating Sales in both At-Home and Clinical Channels
The sales milestone was achieved last month as online awareness of the product grew expansively and clinical providers reached nearly 1,000 locations.
Gateway Genomics, a leading developer of direct-to-consumer genetic tests that give families insight into their future children, announces inclusion in the Inc. 5000 2020 list of fastest growing private companies for the second year in a row. To qualify, companies must have been founded and generating revenue by March 31, 2016. Ranking in the list is determined by the percentage revenue growth from 2016 to 2019, with minimums set for each year. With 1,623% revenue growth from 2016 to 2019, Gateway Genomics ranked #296 in the list, and #22 in the Health sector.
Gateway Genomics Ranks 296 in the Inc. 5000 Fastest-Growing Private Companies in America List for 2020
For the second straight year, Gateway Genomics ranks in the top 25 private companies in the Health sector, which includes biotech, pharmaceutical firms, and makers of medical devices and products for the health care market.
Gateway Genomics, a leading developer of direct-to-consumer genetic tests that give families insight into their future children, announces inclusion in the Inc. 5000 2020 list of fastest growing private companies for the second year in a row. To qualify, companies must have been founded and generating revenue by March 31, 2016. Ranking in the list is determined by the percentage revenue growth from 2016 to 2019, with minimums set for each year. With 1,623% revenue growth from 2016 to 2019, Gateway Genomics ranked #296 in the list, and #22 in the Health sector.
Gateway Genomics Announces Top 7 Reasons Why Women Want to Know Their Baby’s Gender Early
In a new study with over 1,000 participants across the US, UK, and Canada, “satisfying curiosity” was the #1 reason for fetal sex determination at 8 weeks into pregnancy.
Gateway Genomics, leading developer of direct-to-consumer genetic tests that give families insight into their future children, announces a new publication titled, “Reported Benefits of Early Fetal Sex Determination” in the International Journal of Pregnancy & Child Birth. In the study, over 1,000 postpartum moms who had taken the SneakPeek Early Gender DNA Test responded to a survey to share what benefits they received from knowing the gender of their babies early in pregnancy.